Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-MPI-03 in Hematologic Cancer
NCT02240537Phase 1Unknown
- Sponsor
- Benovus Bio, Inc.
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BB-MPI-03 in acute myeloid leukemia (AML), multiple myeloma (MM), smoldering multiple myeloma (SMM) and 1 more, sponsored by Benovus Bio, Inc. Primary endpoints: Safety and Tolerability at 6 months, Dose-Limiting Toxicity at 6 months and 2 more. Status: unknown.
02
Drugs
BB-MPI-03
03
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)smoldering multiple myeloma (SMM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02240537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240537.